. 2017 Jun 1;28(5):e62. doi: 10.3802/jgo.2017.28.e62

Table 3. Univariate and multivariate analyses for OS rate using Cox regression model.

Variables	Subsets	No.	Univariate analysis			Multivariate analysis
Variables	Subsets	No.	HR	95% CI	p-value	HR	95% CI	p-value
FIGO stage	I–II	13	3.64	0.91–14.61	0.068	-	-	-
FIGO stage	III–IV	9	3.64	0.91–14.61	0.068	-	-	-
Carcinoma grade	G1–2	4	31.78	0.46–22,008.54	0.300	-	-	-
Carcinoma grade	G3	18	31.78	0.46–22,008.54	0.300	-	-	-
Sarcomatous component	Homologous	13	2.05	0.55–7.64	0.288	-	-	-
Sarcomatous component	Heterologous	8	2.05	0.55–7.64	0.288	-	-	-
Tumor size (cm)	<7	10	2.14	0.53–8.67	0.285	-	-	-
Tumor size (cm)	≥7	12	2.14	0.53–8.67	0.285	-	-	-
Myometrial invasion	≤1/2	13	1.52	0.41–5.78	0.518	-	-	-
Myometrial invasion	>1/2	9	1.52	0.41–5.78	0.518	-	-	-
LVSI	Absence	12	0.78	0.21–2.95	0.719	-	-	-
LVSI	Presence	10	0.78	0.21–2.95	0.719	-	-	-
Ascites	Negative	15	3.28	0.81–13.28	0.097	-	-	-
Ascites	Positive	6	3.28	0.81–13.28	0.097	-	-	-
LN metastasis	Absence	16	6.38	1.38–29.48	0.018^*	3.761	0.79–17.91	0.096
LN metastasis	Presence	4	6.38	1.38–29.48	0.018^*	3.761	0.79–17.91	0.096
MRI unenhanced region (%)	<10	9	8.29	1.03–67.11	0.047^*	5.381	0.60–47.95	0.312
MRI unenhanced region (%)	≥10	13	8.29	1.03–67.11	0.047^*	5.381	0.60–47.95	0.312

CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; LN, lymph node; LVSI, lymphovascular space invasion; MRI, magnetic resonance imaging; OS, overall survival.

^*p<0.050.